SONY

Product Data Sheet

PE/Cyanine7 anti-human CD32B/C

Catalog # / Size:	2591565 / 25 tests 2591570 / 100 tests
Clone:	S18005H
Isotype:	Mouse IgG1, κ
Immunogen:	Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)
Concentration:	Lot-specific



Human peripheral blood lymphocytes were stained with CD19 FITC and CD32B/C (clone S18005H) PE/Cyanine7 (left) or mouse IgG1, κ PE/Cyanine7 isotype control (right).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	As the extracellular region of CD32B and CD32C are identical, this Ab recognizes both isoforms. Does not crossreact with CD32A.

Description: CD32B (FCGR2B) and CD32C (FCGR2C) are 40 kDa, type I transmembrane proteins that are members of the Ig superfamily of low-affinity immunoglobulin gamma Fc receptors. CD32B has a cytoplasmic tail that contains an immunoreceptor tyrosine-based inhibition motif (ITIM), while CD32C contains an immunoreceptor tyrosine-based activation motif (ITAM). CD32B and CD32C are low affinity receptor for monomeric IgG but also bind IgG complexes. CD32B and CD32C are expressed on B cells, subsets of monocytes,macrophages and granulocytes, platelets, mast cells, and is a negative regulator of cell activation, proliferation, endocytosis, phagocytosis, and degranulation.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

Antigen References:

1. Bruhns P, *et al.* 2009. *Blood.* 113: 3716.
2. Bewarder N, *et al.* 1996. *Mol Cell Biol.* 16: 4735.
3. Descours B, *et al.* 2017. *Nature.* 543: 564.
4. Tomiyama Y, *et al.* 1992. *Blood.* 80: 2261.
5. Indik Z, *et al.* 1991. *J Clin Invest.* 88: 1766.
6. Ramsland PA, *et al.* 2011. *J Immunol.* 187: 3208.
7. Hogarth PM and Pietersz GA. 2012. *Nat Rev Drug Discov.* 11: 311.
8. Bournazos S, *et al.* 2009. *J Immunol.* 182: 8026.
9. Maxwell KF, *et al.* 1999. *Nat Struct Biol.* 6: 437.
10. Sandilands GP, *et al.* 1997. *Immunology.* 91: 204.
11. Ghazizadeh S, *et al.* 1994. *J Biol Chem.* 269: 8878.
12. Gillis C, *et al.* 2014. *Front Immunol.* 5: 254.